Table 2.
Examples of ongoing clinical trials with IL-15.
| Drug | Interventions | Conditions | Status | Phases | Enrollment | NCT No. |
|---|---|---|---|---|---|---|
| rhIL-15 | rhIL-15 + Avelumab | T-cell Malignancies, Renal Carcinoma | Recruiting | I/II | 25 | NCT03905135, NCT04150562 |
| rhIL-15 + Mogamulizumab | T-cell Malignancies | Recruiting | I | 20 | NCT04185220 | |
| rhIL-15 + Obinutuzumab | Chronic Lymphocyte Leukemia | Recruiting | I | 24 | NCT03759184 | |
| rhIL-15 + Ipilimumab + Nivolumab | Refractory Solid Tumors | Recruiting | I | 50 | NCT03388632 | |
| s.c. rhIL-15 + Alemtuzumab | T-cell Malignancies | Recruiting | I | 30 | NCT02689453 | |
| RTX-240 | RTX-240 monotherapy | Adult Solid Tumor | Recruiting | I/II | 172 | NCT04372706 |
| BJ-001 | BJ-001 + Pembrolizumab | Advanced/Metastatic Solid Tumors | Recruiting | I | 92 | NCT04294576 |
| NIZ985 | NIZ985 + PDR001 | Metastatic Solid Tumors | Recruiting | I | 110 | NCT02452268 |
| NIZ985 + Spartalizumab | Solid Tumors and Lymphoma | Recruiting | I | 68 | NCT04261439 | |
| ALT-803 | ALT-803 monotherapy | Hematologic Malignancy | Active, not recruiting | I/II | 61 | NCT01885897 |
| ALT-803 + BCG | Non-muscle Invasive Bladder Cancer | Recruiting | I/II | 596/160 | NCT02138734, NCT03022825 | |
| ALT-803 + Rituximab | B Cell Non-Hodgkin Lymphoma | Active, not recruiting | I/II | 86 | NCT02384954 | |
| ALT-803 + Nivolumab | Non-small Cell Lung Cancer | Active, not recruiting | I/II | 58 | NCT02523469 | |
| ALT-803 + Pembrolizumab/Nivolumab/Atezolizumab | Advanced Cancer | Recruiting | II | 611 | NCT03228667 | |
| ALT-803 + Elotuzumab + Expanded Natural Killer (ENK) Cells | Multiple Myeloma | Recruiting | II | 10 | NCT03003728 | |
| N-803 | N-803 + haNK™ + Avelumab | Merkel Cell Carcinoma | Recruiting | II | 43 | NCT03853317 |
| N-803 + CIML NK cell infusion + Ipilimumab | Head and Neck Squamous Cell Carcinoma | Recruiting | I | 12 | NCT04290546 | |
| Adoptive Cell Therapy/Engineered Cell | Donor IL-15-stimulated NK cells infusion | Acute Leukemia | Recruiting | I/II | 3 | NCT03669172 |
| IL-2 or IL-7/IL-15 pretreated CD19 cells | B Cell Lymphoma | Not yet recruiting | IV | 10 | NCT02992834 | |
| iC9.GD2.CAR.IL-15 T-cells | Neuroblastoma | Recruiting | I | 18 | NCT03721068 | |
| CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells | Lymphoblastic Leukemia | Not yet recruiting | I | 12 | NCT03579888 | |
| GINAKIT Cells (GD2.CAR.IL-15 NKT Cells) | Neuroblastoma | Recruiting | I | 24 | NCT03294954 | |
| GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE™) | High Risk Heme Malignancies | Recruiting | I/II | 60 | NCT03214666 | |
| iC9/CAR.19/IL15-transduced CB-NK cells + AP1903 | Lymphoid Malignancies | Recruiting | I/II | 36 | NCT03056339 |
rhIL-15: recombinant human IL-15; BCG: Bacillus Calmette-Guérin; CIML: Cytokine-induced memory-like; s.c. subcutaneous.